Company: NIVFW
Filing Date: 2025-09-15
Form Type: F-1
Source: 0001213900-25-087717
Chunk: 186

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-15
Form: F-1
Chunk 186
---
 be settled by
way of the issuance of (pre Reverse Stock Splits) of its ordinary shares to the shareholder(s) of COVIRIX or their respective
nominees (the “COVIRIX Shareholders”) in exchange for % equity interest of COVIRIX, at a deemed price per share of US$,
representing an aggregate amount of US$. Simultaneously, it is proposed that COVIRIX undertakes to introduce investors to raise
US$ million at US$ per share for NIVF, in a form mutually acceptable to both NewGen and COVIRIX. Following stockholder approval of the
Proposed Transaction, COVIRIX Shareholders are expected to hold approximately % equity interest in NewGen. However, on September 21,
2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company.

On August 7, 2024, the Company
entered into a Securities Purchase Agreement with certain investors named therein (collectively, the “Buyers”), pursuant to
which, amongst other things: (i) the Company agreed to sell, at an initial closing with JAK Opportunities VI LLC (“JAK” and
such initial closing, the “Initial Closing”), pursuant to which the Company agreed to sell to JAK (a) a senior convertible
note (the “Initial Note”) in the aggregate original principal amount of $, and which terms are further set forth
below under the subheading “(ii) Initial Closing with JAK”, (b) a warrant to purchase Class A Ordinary Shares of
the Company (subject to Reverse Stock Split adjustments), no par value (“Class A Shares” and such warrant, the Series A Warrant),
and (c) a warrant to purchase Class B Ordinary Shares (subject to Reverse Stock Split adjustments) of the Company, no par value
(“Class B Shares” and such warrant, the Series B Warrant, and the Series B Warrants, together with the Series A Warrants,
the “Warrants”); and (ii) the Company may require each Buyer (or each Buyer may require the Company, as applicable) to participate
in the sale of (a) one or more additional convertible notes (which aggregate original principal amount for all additional convertible
notes shall not exceed $) (the “Additional Notes,” and, together with the Initial Note, the “Notes”).

On August 12, 2024, the Company